884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies

BACKGROUND: Cabotegravir (CAB) and rilpivirine (RPV) are under development as a novel long-acting (LA) regimen for maintenance of HIV virologic suppression. Pooled Week 48 data from pivotal Phase 3 trials demonstrated noninferiority of CAB LA + RPV LA vs. current antiretroviral regimen (CAR) on the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Teichner, Paula, Cutrell, Amy, D’Amico, Ronald, Dorey, David, Griffith, Sandy, Harrington, Conn M, Huang, Jenny, Hudson, Krischan J, Margolis, David, Mrus, Joseph, Polli, Joseph, Spreen, William, Williams, Peter, Van Solingen-Ristea, Rodica, Shaefer, Mark S
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809202/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.043
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados